Observational studyJournal of neuroinflammation2025
Deep immunophenotyping in aneurysmal subarachnoid hemorrhage: a prospective and controlled clinical study.
Observational study in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal immune profiling demonstrates persistent MAIT cell reduction and temporal cytokine alterations after aneurysmal subarachnoid hemorrhage.Frontiers in neurology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAneurysmal subarachnoid hemorrhage (aSAH) remains a devastating cerebrovascular condition with significant morbidity and mortality. While inflammation plays a critical role in post-hemorrhagic complications, the specific polarization dynamics of monocyte and T cell subpopulations in this context remain poorly understood. This study aims to investigate these immune cell shifts and their correlation with major complications such as angiographic cerebral vasospasm and delayed cerebral ischemia (DCI).
methodsWe conducted a prospective, controlled observational single-center cohort study in a neurovascular university center of maximum care in Germany. A total of 75 patients with aSAH and 20 healthy controls were included. Blood samples were collected on days 1, 4, 7, and 11 post-bleeding. Flow cytometry was used to analyze monocyte (M1, intermediate, M2) and T cell (Th1, Th2, Th17, Treg) polarization patterns. Primary outcomes included the incidence of angiographic cerebral vasospasm, clinical DCI and/or cerebral infarction due to DCI, and clinical outcome assessed at 6 months via the modified Rankin Scale (mRS).
resultsCompared to healthy controls, patients with aSAH exhibited a significant decrease in anti-inflammatory alternatively activated monocytes (6.3% vs. 3.0%; p = 0.04) within 24 h post-bleeding, an increase in pro-inflammatory Th17 T cells (36.3% vs. 6.2%; p < 0.001) and decrease in anti-inflammatory Th2 cells (45.5% vs. 75.2%; p < 0.001). A loss of anti-inflammatory alternatively activated monocytes was observed prior to the onset of angiographic cerebral vasospasm (3.8% vs. 2.7%; p = 0.031) and DCI (4.2% vs. 2.9%; p = 0.006). No significant correlation was found between immune cell subpopulations and long-term clinical outcomes.
conclusionsThis study demonstrates a shift toward pro-inflammatory immune cell subpopulations following aSAH, with significant losses of alternatively activated monocytes preceding major complications such as vasospasm and DCI. These findings suggest that immune subpopulation profiling may hold potential as a diagnostic and therapeutic tool in the context of aSAH-related complications. Future studies should aim to clarify whether the observed peripheral immune changes reflect analogous intracerebral immune mechanisms and whether modulating these pathways can improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.